Recently, a novel strategy to specifically target eIF4E activity in ovarian cancer models has been reported, where 4E-BP1 peptides were fused to an agonist of the gonadotropin-releasing hormone (GnRH)[84], thereby mediating the uptake and showing a marked decrease in tumor cells growth. The gene discussed is EIF4E; the disease is neoplasm.